Reports

Félicien  Girardin

Félicien Girardin

Manager France & Benelux


Tel. +41 32 420 52 27

felicien.notexisting@nodomain.comgirardin@baselarea.notexisting@nodomain.comswiss
report Invest in Basel region
Medtech Lab in Courroux. (img: Thomas Jantscher)

Medtech Lab in Courroux. (img: Thomas Jantscher)

12.03.2018

Indian biotechnology firm to build plant in the Canton of Jura

Protaccine Biotec Sàrl, a manufacturer of antiserums, vaccines and other biotech products for fighting deadly diseases, plans to build a production unit at the Innodel industrial park in Courroux.

This major investment should create over 40 skilled jobs in the medium term. The man behind the project, Dr Anil Kumar Chawla, CEO of New Delhi-based Chimera Gentec Pvt Ltd, is thrilled to be developing innovative pharmaceutical products in the Canton of Jura. "To help market the products that we develop, we immediately identified Switzerland as a target country because we wanted to be close to organisations like the WHO, UNOG and Swissmedic, whom we have already worked with."

Initially, the company has decided to rent space in the medtech.lab, also located in the Innodel park, so that production can start as soon as possible. The new plant will be built at the same time.

This investment is the result of close collaboration between BaselArea.swiss and the Canton of Jura's Economic Promotion department. Contact was made with the regional authorities several months ago, which enabled Protaccine Biotec Sàrl to be guided through the entire startup process. The proximity of the Basel metropolitan area, with its strong biotechnology industry and highly qualified workforce, coupled with the attractive business environment offered by the Canton of Jura were key in bringing this plant to Courroux.

The Canton of Jura's Minister for the Economy and Health, Jacques Gerber, was delighted at this investment, which is part of the Jura's economic diversification policy.

Cookies

BaselArea.swiss uses cookies to ensure you get the best service on our website.
By continuing to browse the site, you are agreeing to the use of cookies.

Ok